CMPS
COMPASS Pathways Plc−$3.15 (27.19%) At close $8.42 · Today
☾After Hours +$0.31 (3.70%) Nov 2, 4:45 PM ET
About CMPS
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Cylvex Score
Multiple risk signals, limited coverage
Multi-factor score. Not a buy/sell signal.
Score history
CalibratingScore history is calibrating — it appears once enough daily scores are recorded.
What goes into the score
6 axes · equal weightThe Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.